{"title": "Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/top/health.xml", "value": "Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190326122155.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190326122155.htm", "summary": "A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/top/health.xml", "value": "A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action."}, "published": "Tue, 26 Mar 2019 12:21:55 EDT", "published_parsed": [2019, 3, 26, 16, 21, 55, 1, 85, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190326122155.htm", "guidislink": false}